3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
11
Somatostatinoma
6
Insulinoma
4
Glucagonoma
4
Gastrinoma
4
Carcinoma, Neuroendocrine
4
Carcinoma, Islet Cell
3
Zollinger-Ellison Syndrome
2
Vipoma
2
Pheochromocytoma
2
Pancreatic Neoplasms
2
Carcinoma, Medullary
2
Carcinoid Tumor
2
Adenoma, Islet Cell
2
Pituitary Neoplasms
1
Non functioning pancreatic endocrine tumor
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 2b
1
Multiple Endocrine Neoplasia Type 2a
1
Multiple Endocrine Neoplasia Type 1
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gastro-entero-pancreatic Neuroendocrine Tumors
1
Carcinoma, Merkel Cell
1
Adrenal Cortex Neoplasms
1
Interventions
lutetium Lu 177 dotatate
8
lanreotide
4
copper dotatate CU-64
4
Octreotide
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
pasireotide
3
Magnetic Resonance Spectroscopy
3
Lutetium-177
3
Lutetium
3
gallium Ga 68 dotatate
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Nivolumab
2
Irinotecan
2
Ga(III)-DOTATOC
2
Everolimus
2
Etoposide
2
Carboplatin
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
irinotecan sucrosofate
1
folfirinox
1
famitinib
1
cabozantinib
1
arginyllysine
1
abemaciclib
1
X-Rays
1
Sunitinib
1
Somatostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Capecitabine
×
Endocrine
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled